Characteristics of Preapproval and Postapproval Studies of Vaccines Granted Accelerated Approval by the US Food and Drug Administration

被引：0
|
作者：
Alexander Egilman
Joshua D. Wallach
Jeremy Puthumana
Audrey D. Zhang
Jason L. Schwartz
Joseph S. Ross
机构：
[1] Yale-New Haven Hospital,Center for Outcomes Research and Evaluation
[2] Yale School of Public Health,Department of Environmental Health Sciences
[3] Yale School of Medicine,Department of Internal Medicine
[4] Duke University School of Medicine,Department of Medicine
[5] Yale School of Public Health,Department of Health Policy and Management
来源：
Journal of General Internal Medicine | 2021年 / 36卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3281 / 3284
页数：3
相关论文
共 50 条
  • [21] Accelerated Approval of Oncology Products: The Food and Drug Administration Experience
    Johnson, John R.
    Ning, Yang-Min
    Farrell, Ann
    Justice, Robert
    Keegan, Patricia
    Pazdur, Richard
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (08) : 636 - 644
  • [22] Availability and Dissemination of Results From US Food and Drug Administration-Mandated Postapproval Studies for Medical Devices
    Quesada, Odayme
    Yang, Erin
    Redberg, Rita F.
    JAMA INTERNAL MEDICINE, 2016, 176 (08) : 1221 - 1223
  • [23] US food and drug administration drug approval summary: Conversion of imatinib mesylate (ST1571; Gleevec) tablets from accelerated approval to full approval
    Cohen, MH
    Johnson, JR
    Pazdur, R
    CLINICAL CANCER RESEARCH, 2005, 11 (01) : 12 - 19
  • [24] Food and Drug Administration approval process for ophthalmic drugs in the US
    Lloyd, Rhea
    Harris, Jennifer
    Wadhwa, Sonal
    Chambers, Wiley
    CURRENT OPINION IN OPHTHALMOLOGY, 2008, 19 (03) : 190 - 194
  • [25] Transparency and Dermatologic Device Approval by the US Food and Drug Administration
    Ezaldein, Harib H.
    Scott, Jeffrey F.
    Yin, Emily S.
    Ventura, Alessandra
    DeRuyter, Nicholaas P.
    Leffell, David J.
    JAMA DERMATOLOGY, 2018, 154 (03) : 273 - 280
  • [26] Characteristics of Clinical Studies Used for US Food and Drug Administration Approval of High-Risk Medical Device Supplements
    Zheng, Sarah Y.
    Dhruva, Sanket S.
    Redberg, Rita F.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (07): : 619 - 625
  • [27] Product Approval and Public Health at the US Food and Drug Administration
    Lurie, Peter
    Sharfstein, Joshua M.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (24): : 2469 - 2470
  • [28] Inclusion of Training Patients in US Food and Drug Administration Premarket Approval Cardiovascular Device Studies
    Chen, Connie E.
    Dhruva, Sanket S.
    Bero, Lisa A.
    Redberg, Rita F.
    ARCHIVES OF INTERNAL MEDICINE, 2011, 171 (06) : 534 - 539
  • [29] Reforming Reimbursement for the US Food and Drug Administration's Accelerated Approval Program to Support State Medicaid Programs
    Sachs, Rachel E.
    Donohue, Julie M.
    Dusetzina, Stacie B.
    JAMA HEALTH FORUM, 2022, 3 (11): : E224115
  • [30] The US Food and Drug Administration Cardiorenal Advisory Panel and the drug approval process
    Roden, DM
    Temple, R
    CIRCULATION, 2005, 111 (13) : 1697 - 1702
12345